Dexcom (DXCM) Gross Profit (2016 - 2026)
Dexcom has reported Gross Profit over the past 17 years, most recently at $750.3 million for Q1 2026.
- Quarterly Gross Profit rose 27.39% to $750.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Mar 2026, up 20.2% year-over-year, with the annual reading at $2.8 billion for FY2025, 14.92% up from the prior year.
- Gross Profit was $750.3 million for Q1 2026 at Dexcom, down from $792.7 million in the prior quarter.
- Over five years, Gross Profit peaked at $792.7 million in Q4 2025 and troughed at $398.1 million in Q1 2022.
- The 5-year median for Gross Profit is $593.8 million (2024), against an average of $597.8 million.
- Year-over-year, Gross Profit fell 4.73% in 2024 and then grew 27.39% in 2026.
- A 5-year view of Gross Profit shows it stood at $541.3 million in 2022, then grew by 21.3% to $656.6 million in 2023, then fell by 0.12% to $655.8 million in 2024, then grew by 20.88% to $792.7 million in 2025, then dropped by 5.35% to $750.3 million in 2026.
- Per Business Quant, the three most recent readings for DXCM's Gross Profit are $750.3 million (Q1 2026), $792.7 million (Q4 2025), and $731.4 million (Q3 2025).